– ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million, ...
Hosted on MSN
Kiniksa outlines $900M–$920M 2026 ARCALYST revenue guidance as market penetration deepens
Earnings Call Insights: Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Sanj Patel, CEO, stated that "ARCALYST revenue continues to grow, driven by the expanding adoption of IL-1 alpha and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results